

Filip Janku

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6282807/filip-janku-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

146 papers	9,244 citations	46 h-index	95 g-index
156 ext. papers	11,097 ext. citations	6.7 avg, IF	6.31 L-index

#	Paper	IF	Citations
146	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100197	3.6	2
145	A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA. <i>Scientific Reports</i> , 2021 , 11, 19653	4.9	3
144	Hormonal modulation of ESR1 mutant metastasis. <i>Oncogene</i> , 2021 , 40, 997-1011	9.2	10
143	Associations between the gut microbiome and fatigue in cancer patients. <i>Scientific Reports</i> , 2021 , 11, 5847	4.9	6
142	First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. <i>Investigational New Drugs</i> , 2021 , 39, 1348-1356	4.3	3
141	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. <i>Investigational New Drugs</i> , 2021 , 39, 1357-1365	4.3	0
140	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 4491-4499	12.9	25
139	Intratumoral Injection of -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 96-106	12.9	12
138	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021 , 19, 395-402	6.6	3
137	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. <i>Cancer</i> , 2021 , 127, 391-402	6.4	1
136	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 1247-1255	12.9	1
135	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 13	8.5	1
134	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. <i>Scientific Reports</i> , 2021 , 11, 3667	4.9	6
133	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 2723-2733	12.9	12
132	Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. <i>Cancers</i> , 2021 , 13,	6.6	7
131	Ripretinib inpatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2021 , 155, 236-244	7.5	2
130	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory 2020 , 8,		5

129	Ivosidenib in Isocitrate Dehydrogenase 1 Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3398-3406	2.2	65
128	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1924-1931	12.9	26
127	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1693-1701	2.2	40
126	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 1237-1246	12.9	33
125	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020 , 10, 3080	4.9	3
124	Phase 2 study of pembrolizumab in patients with advanced rare cancers 2020 , 8,		45
123	RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients. <i>Journal of Cancer</i> , 2020 , 11, 3543-3550	4.5	4
122	Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2504-2504	2.2	2
121	The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3547-3547	2.2	4
120	Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3590-3590	2.2	3
119	Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3640-3640	2.2	4
118	Intratumor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15223-e15223	2.2	
117	A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS3162-TPS3162	2.2	1
116	An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6085-6085	2.2	
115	Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS6590-TPS6590 ¹	2.2	1
114	Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of cancer therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3533-3533	2.2	
113	Incorporating Circulating Biomarkers into Clinical Trials 2020 , 233-247		
112	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5579-5587	12.9	5

111	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3294-3303	2.2	31
110	Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. <i>Oncologist</i> , 2020 , 25, e160-e169	5.7	31
109	Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. <i>Cancer Cell</i> , 2019 , 35, 738-751.e9	24.3	93
108	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1149-1157	6.1	16
107	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. <i>Oncologist</i> , 2019 , 24, 219-228	5.7	17
106	Liquid Biopsies Using Plasma Exosomal Nucleic Acids. <i>Oncoscience</i> , 2019 , 6, 296-297	0.8	1
105	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 711-720	18.8	110
104	Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors 2019 ,		2
103	Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3014-3014	2.2	25
102	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	3
101	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 145	22.4	17
100	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019 , 125, 463-472	6.4	7
99	Targeting the PI3K pathway in cancer: are we making headway?. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 273-291	19.4	491
98	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018 , 8, 184-195	24.4	198
97	Advances on the BRAF Front in Colorectal Cancer. <i>Cancer Discovery</i> , 2018 , 8, 389-391	24.4	6
96	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018 , 24, 181-188	12.9	89
95	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018 , 23, 1300-1309	5.7	28
94	Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2002-2002	2.2	22

93	Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 33258-33270	3.3	4
92	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 671-676	6.1	23
91	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018 , 36, 638-646	4.3	102
90	Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	8
89	Phosphatidylinositol 3-Kinase Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1291-1299	2.2	190
88	Phase I Trial of Dabrafenib and Pazopanib in Mutated Advanced Malignancies.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-19	3.6	
87	Moving Precision Oncology Forward Amid Myths and Misconceptions. <i>JAMA Oncology</i> , 2018 , 4, 1788-1789	3.4	1
86	A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 407-418	3.5	37
85	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017 , 23, 3657-3666	12.9	44
84	Circulating tumor DNA-From bench to bedside. <i>Current Problems in Cancer</i> , 2017 , 41, 212-221	2.3	1
83	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. <i>JAMA Oncology</i> , 2017 , 3, 509-515	13.4	97
82	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5648-5656	12.9	38
81	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. <i>Oncotarget</i> , 2017 , 8, 39254-39267	3.3	38
80	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	67
79	Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. <i>Cancer Treatment Reviews</i> , 2017 , 59, 93-101	14.4	138
78	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017 , 7, 15963	4.9	17
77	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials 2017 , 5, 100		67
76	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. <i>Oncoscience</i> , 2017 , 4, 47-56	0.8	16

75	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. <i>Oncotarget</i> , 2017 , 8, 33796-33806	3.3	3
74	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2475-2485	6.1	49
73	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. <i>Cancer Discovery</i> , 2016 , 6, 1352-1365	24.4	150
72	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1397-404	6.1	61
71	Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2016 , 34, e34-7	2.2	9
70	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016 , 6, 154-65	24.4	269
69	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016 , 7, 67521-67531	3.3	36
68	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. <i>Oncoscience</i> , 2016 , 3, 164-72	0.8	29
67	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016 , 6, 35448	4.9	9
66	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016 , 5, 3437-3444	4.8	12
65	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016 , 76, 3690-701	10.1	154
64	Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 533-47	6.1	46
63	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1764-71	2.2	102
62	Bringing Blood-Based Molecular Testing to the Clinic. <i>Clinical Cancer Research</i> , 2016 , 22, 5400-5402	12.9	7
61	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 215-24	4.3	6
60	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015 , 33, 177-86	4.3	20
59	Cell-free DNA as a novel marker in cancer therapy. <i>Biomarkers in Medicine</i> , 2015 , 9, 703-12	2.3	10
58	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>Investigational New Drugs</i> , 2015 , 33, 700-9	4.3	11

57	Targeted therapies for advanced Ewing sarcoma family of tumors. <i>Cancer Treatment Reviews</i> , 2015 , 41, 391-400	14.4	20
56	Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. <i>Journal of Medical Case Reports</i> , 2015 , 9, 45	1.2	4
55	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2753-62	2.2	295
54	Multiple gene aberrations and breast cancer: lessons from super-responders. <i>BMC Cancer</i> , 2015 , 15, 442	4.8	11
53	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4032-8	2.2	424
52	Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. <i>Cancer Discovery</i> , 2015 , 5, 64-71	24.4	101
51	HER2/neu-directed therapy for biliary tract cancer. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 58	22.4	149
50	The mu opioid receptor: A new target for cancer therapy?. <i>Cancer</i> , 2015 , 121, 2681-8	6.4	46
49	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. <i>Oncotarget</i> , 2015 , 6, 12809-21	3.3	77
48	Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 1631-44	3.8	39
47	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 730-8	12.9	215
46	Challenges and perspective of drug repurposing strategies in early phase clinical trials. <i>Oncoscience</i> , 2015 , 2, 576-80	0.8	29
45	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015 , 6, 26886-94	3.3	38
44	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. <i>Pharmacology & Therapeutics</i> , 2014 , 142, 164-75	13.9	520
43	Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. <i>Clinical Cancer Research</i> , 2014 , 20, 4827-36	12.9	150
42	Erdheim-Chester disease: characteristics and management. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 985-96	6.4	50
41	Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. <i>PLoS ONE</i> , 2014 , 9, e93676	3.7	28
40	Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. <i>Oncotarget</i> , 2014 , 5, 3012-22	3.3	67

39	Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. <i>Science Translational Medicine</i> , 2014 , 6, 249ra111	17.5	202
38	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. <i>Cell Reports</i> , 2014 , 6, 377-87	10.6	186
37	FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. <i>PLoS ONE</i> , 2014 , 9, e89388	3.7	42
36	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. <i>Oncoscience</i> , 2014 , 1, 522-530	0.8	6
35	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. <i>Oncotarget</i> , 2014 , 5, 2349-54	3.3	50
34	BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. <i>Oncotarget</i> , 2014 , 5, 3607-10	3.3	56
33	Characteristics and survival of patients with advanced cancer and p53 mutations. <i>Oncotarget</i> , 2014 , 5, 3871-9	3.3	10
32	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. <i>Oncotarget</i> , 2014 , 5, 8937-46	3.3	6
31	Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. <i>Oncotarget</i> , 2014 , 5, 11168-79	3.3	47
30	Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. <i>Targeted Oncology</i> , 2013 , 8, 183-188	5	5
29	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. <i>Cancer Research</i> , 2013 , 73, 276-84	10.1	221
28	A tale of two histiocytic disorders. <i>Oncologist</i> , 2013 , 18, 2-4	5.7	9
27	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2857-63	6.1	35
26	Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e19-20	8.9	24
25	Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. <i>Oncotarget</i> , 2013 , 4, 884-93	3.3	18
24	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. <i>Oncotarget</i> , 2013 , 4, 772-84	3.3	15
23	A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. <i>Oncotarget</i> , 2013 , 4, 463-73	3.3	23
22	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. <i>Oncotarget</i> , 2013 , 4, 705-14	3.3	87

21	Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012 , 118, 1422-8	6.4	65
20	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. <i>Journal of Clinical Oncology</i> , 2012 , 30, 777-82	2.2	355
19	Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. <i>Clinical Cancer Research</i> , 2012 , 18, 6373-83	12.9	391
18	Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 892-3	2.2	2
17	Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. <i>Clinical Cancer Research</i> , 2012 , 18, 6356-63	12.9	20
16	PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10510-10510	2.2	8
15	KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. <i>PLoS ONE</i> , 2012 , 7, e38033	3.7	38
14	PIK3CA mutations in advanced cancers: characteristics and outcomes. <i>Oncotarget</i> , 2012 , 3, 1566-75	3.3	71
13	Autophagy as a target for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 528-39	19.4	595
12	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. <i>PLoS ONE</i> , 2011 , 6, e22769	3.7	153
11	BRAF mutations in advanced cancers: clinical characteristics and outcomes. <i>PLoS ONE</i> , 2011 , 6, e25806	3.7	72
10	Novel therapeutic targets in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1601-12	8.9	110
9	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 558-65	6.1	281
8	Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement. <i>Irish Journal of Medical Science</i> , 2011 , 180, 765-6	1.9	2
7	Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. <i>Oncologist</i> , 2011 , 16, 327-35	5.7	8
6	A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. <i>Clinical Cancer Research</i> , 2011 , 17, 6840-6	12.9	42
5	Response of histiocytoses to imatinib mesylate: fire to ashes. <i>Journal of Clinical Oncology</i> , 2010 , 28, e633-6	3.6	59
4	Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. <i>Clinical Cancer Research</i> , 2010 , 16, 4031-7	12.9	15

3	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 401-14	19.4	205
2	KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. <i>Melanoma Research</i> , 2005 , 15, 251-6	3.3	34
1	4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. <i>Bulletin Du Cancer</i> , 2004 , 91, E279-83	2.4	5